iShares S&P 500 Etf

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

EML Payments Limited

EML

EML Payments Ltd. engages in the provision of payment solutions and financial services. The company is headquartered in Brisbane, Queensland and currently employs 642 full-time employees. The company went IPO on 2006-01-18. The firm offers program management and payments expertise to create customizable solutions for businesses, brands and their customers. The firm operates through three segments: General Purpose Reloadable (GPR), Gift & Incentive (G&I), and Digital Payments (DP). GPR segment products provide reloadable cards to a variety of industries, including, Government, Salary Packaging, Gaming and Digital Banking. This segment also provides a full-service offering, including issuance, processing and program management. Its G&I segment products provide single load gift cards for shopping malls and incentive programs across the world. Its DP segment products provide payment options for consumers. Industries include Open Banking, Buy-Now Pay-Later providers and Bill payment providers. The firm's products include Card Payments, Open Banking, Digital Account Payments and Seamless.

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares Etf

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its HER-Vaxx is a B-cell immuno-therapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. PD1-Vaxx is a B-cell immuno-therapy, which aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer. Its clinical trial candidates include VAXINIA, CHECKvacc, B-Vaxx and others. Its platform technologies seek to harness the body’s immune system against tumors.